Association between ACR1 gene product expression and cardiomyopathy in children

Wang,Yan; Niu,Ling; He,Xiuhua; Xue,Ying; Ling,Nan; Wang,Zhenzhou; An,Xinjiang

doi:10.3892/etm.2016.3510

Association between ACR1 gene product expression and cardiomyopathy in children

Authors:
- Yan Wang
- Ling Niu
- Xiuhua He
- Ying Xue
- Nan Ling
- Zhenzhou Wang
- Xinjiang An
View Affiliations

Affiliations: Department of Cardiology, Xuzhou Children's Hospital, Xuzhou, Jiangsu 221002, P.R. China
Published online on: July 5, 2016 https://doi.org/10.3892/etm.2016.3510
Pages: 1711-1714
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cardiomyopathy is a heterogeneous heart disease. Although morbidity of pediatric cardiomyopathy has been on the increase, effective treatments have not been identified. The aim of the study was to examine the expression of ACR1 gene products in association with cardiomyopathy in children. In total, 73 patients and 76 healthy subjects were enrolled in the study, from April, 2013 to April, 2015. The relative expression of ACR1 mRNA and protein were quantified in all cases, using reverse transcription-quantitative polymerase chain reaction (RT-qPCR), ELISA and western blot analysis. Immunohistochemistry was used to stain cardiac tissue samples to reveal differences between the patients and the control group. The results showed that the level of ACR1 mRNA by RT‑qPCR was not different between the two study groups. However, ELISA and western blot analysis showed a significant difference, with patients expressing lower levels of ACR1. Additionally, immunohistochemistry revealed the levels of ACR1 were reduced in patients as the time course of disease increased. Thus, there is an association between the inhibition of ACR1 expression and the development of the disease. These findings are useful in the elucidation of the pathogenesis of pediatric cardiomyopathy, a severe disease with few effective treatment options available.

View Figures

View References

1	Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, Gatehouse PD, Arai AE, Friedrich MG, Neubauer S, et al: Society for Cardiovascular Magnetic Resonance Imaging; Cardiovascular Magnetic Resonance Working Group of the European Society of Cardiology: Myocardial T1 mapping and extracellular volume quantification: A Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 15:922013. View Article : Google Scholar : PubMed/NCBI
2	Malhotra A, Kahlon P, Donoho T and Doyle IC: Pharmacogenomic considerations in the treatment of the pediatric cardiomyopathy called Barth syndrome. Recent Pat Biotechnol. 8:136–143. 2014. View Article : Google Scholar : PubMed/NCBI
3	Pankuweit S, Richter A, Ruppert V and Maisch B: Classification of cardiomyopathies and indication for endomyocardial biopsy revisited. Herz. 34:55–62. 2009.(In German). View Article : Google Scholar : PubMed/NCBI
4	Yoo SJ, Grosse-Wortmann L and Hamilton RM: Magnetic resonance imaging assessment of arrhythmogenic right ventricular cardiomyopathy/dysplasia in children. Korean Circ J. 40:357–367. 2010. View Article : Google Scholar : PubMed/NCBI
5	Kipps AK, Ramamoorthy C, Rosenthal DN and Williams GD: Children with cardiomyopathy: Complications after noncardiac procedures with general anesthesia. Paediatr Anaesth. 17:775–781. 2007. View Article : Google Scholar : PubMed/NCBI
6	Colan SD, Lipshultz SE, Lowe AM, Sleeper LA, Messere J, Cox GF, Lurie PR, Orav EJ and Towbin JA: Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: Findings from the Pediatric Cardiomyopathy Registry. Circulation. 115:773–781. 2007. View Article : Google Scholar : PubMed/NCBI
7	Xu Z, Huang M, Jun L and Zhang Y: Review on Diagnosis and Treatment of cardiomyopathy of Children for 10 Year. J Clin Pediatr. 4:345–348. 2011.
8	Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kühl U, Maisch B, McKenna WJ, et al: Classification of the cardiomyopathies: A position statement from the european society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. 29:270–276. 2008. View Article : Google Scholar : PubMed/NCBI
9	Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, Dobbels F, Kirk R, Rahmel AO and Hertz MI: International Society of Heart and Lung Transplantation: The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report - 2012. J Heart Lung Transplant. 31:1052–1064. 2012. View Article : Google Scholar : PubMed/NCBI
10	Alkaladi A, Abdelazim AM and Afifi M: Antidiabetic activity of zinc oxide and silver nanoparticles on streptozotocin-induced diabetic rats. Int J Mol Sci. 15:2015–2023. 2014. View Article : Google Scholar : PubMed/NCBI
11	Kishimoto S, Suda K, Yoshimoto H, Teramachi Y, Nishino H, Koteda Y, Itoh S, Kudo Y, Iemura M and Matsuishi T: Thirty-year follow-up of carnitine supplementation in two siblings with hypertrophic cardiomyopathy caused by primary systemic carnitine deficiency. Int J Cardiol. 159:e14–e15. 2012. View Article : Google Scholar : PubMed/NCBI
12	Takahashi R, Asai T, Murakami H, Murakami R, Tsuzuki M, Numaguchi Y, Matsui H, Murohara T and Okumura K: Pressure overload-induced cardiomyopathy in heterozygous carrier mice of carnitine transporter gene mutation. Hypertension. 50:497–502. 2007. View Article : Google Scholar : PubMed/NCBI
13	Towbin JA: Cardiomyopathy and heart transplantation in children. Curr Opin Cardiol. 17:274–279. 2002. View Article : Google Scholar : PubMed/NCBI
14	Sarafoglou K, Tridgell AHC, Bentler K, Redlinger-Grosse K, Berry SA and Schimmenti LA: Cardiac conduction improvement in two heterozygotes for primary carnitine deficiency on L-carnitine supplementation. Clin Genet. 78:191–194. 2010. View Article : Google Scholar : PubMed/NCBI
15	Li FY, El-Hattab AW, Bawle EV, Boles RG, Schmitt ES, Scaglia F and Wong LJ: Molecular spectrum of SLC22A5 (OCTN2) gene mutations detected in 143 subjects evaluated for systemic carnitine deficiency. Hum Mutat. 31:E1632–E1651. 2010. View Article : Google Scholar : PubMed/NCBI
16	Wexler RK, Elton T, Pleister A and Feldman D: Cardiomyopathy: An overview. Am Fam Physician. 79:778–784. 2009.PubMed/NCBI
17	Hershberger RE, Cowan J, Morales A and Siegfried JD: Progress with genetic cardiomyopathies: Screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail. 2:253–261. 2009. View Article : Google Scholar : PubMed/NCBI
18	Murphy RT, Thaman R, Blanes JG, Ward D, Sevdalis E, Papra E, Kiotsekoglou A, Tome MT, Pellerin D, McKenna WJ and Elliott PM: Natural history and familial characteristics of isolated left ventricular non-compaction. Eur Heart J. 26:187–192. 2005. View Article : Google Scholar : PubMed/NCBI
19	Escher F, Vetter R, Kühl U, Westermann D, Schultheiss HP and Tschöpe C: Fractalkine in human inflammatory cardiomyopathy. Heart. 97:733–739. 2011. View Article : Google Scholar : PubMed/NCBI
20	Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, Messere J, Cox GF, Lurie PR, Hsu D, et al: Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 296:1867–1876. 2006. View Article : Google Scholar : PubMed/NCBI